Tibotec Files NNRTI Rilpivirine, Part Of Gilead's New Combo For HIV
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Johnson & Johnson subsidiary Tibotec has submitted its once-daily non-nucleoside reverse transcriptase inhibitor TMC278 (rilpivirine) for treatment-naïve HIV patients for FDA approval, close on the heels of releasing pivotal data at the International AIDS Society meeting in Vienna